Paper Details

  1. Home
  2. Paper Details

Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease.

Author: LeeJae-Hong, SevignyJeff

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the tolerability of rivastigmine transdermal patch and rivastigmine capsules in patients with Alzheimer's disease. The patch was well tolerated regardless of body weight, whereas patients with lower body weight receiving capsules experienced more adverse events.
Paper Details　
Original Abstract of the Article :
The rationale for the development of the rivastigmine transdermal patch was to improve upon an efficacious therapy by mitigating certain adverse events, such as nausea and vomiting. This may be particularly important in Alzheimer disease patients with low body weights, who may be more susceptible to...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/WAD.0b013e3181f32829

データ提供：米国国立医学図書館（NLM）

Rivastigmine Patch: A Patient-Friendly Approach to Alzheimer's Treatment

This study examines the tolerability of rivastigmine transdermal patch in Alzheimer's disease patients, focusing on the impact of body weight. It's like navigating a challenging desert, finding ways to optimize treatment for a complex and debilitating disease. The study found that rivastigmine patch was generally well-tolerated regardless of body weight, while oral rivastigmine was associated with higher adverse event rates in patients with lower body weights. This study highlights the potential benefits of using rivastigmine patch, particularly for patients with lower body weights.

A New Frontier in Alzheimer's Treatment

This study provides valuable insights into the tolerability of rivastigmine patch, a medication used to treat Alzheimer's disease. It's like finding a new path through a treacherous desert, seeking ways to improve the lives of those suffering from this debilitating condition. The study found that the patch was well-tolerated and offered a viable alternative to oral administration, particularly for patients with lower body weights.

Towards Better Treatment Options for Alzheimer's

This study sheds light on the potential benefits of the rivastigmine patch for Alzheimer's patients. It's like discovering a hidden well in the desert, offering a refreshing solution to a challenging problem. The study's findings suggest that the patch may offer a more tolerable and effective treatment option for patients with lower body weights.

Dr.Camel's Conclusion

This study is a beacon of hope in the search for better treatment options for Alzheimer's disease. It highlights the importance of considering individual patient factors and finding ways to optimize therapy for the best possible outcomes. It's a reminder that with innovation and research, we can continue to make progress in combating this devastating disease.

Date :
  1. Date Completed 2011-06-08
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

20975519

DOI: Digital Object Identifier

10.1097/WAD.0b013e3181f32829

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.